Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

ClinicalTrials.gov ID: NCT07290569

Public ClinicalTrials.gov record NCT07290569. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Study identification

NCT ID
NCT07290569
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2, 2025
Primary completion
May 31, 2027
Completion
Nov 30, 2028
Last update posted
Aug 16, 2026

2025 – 2028

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Oruka Therapeutics Investigative Site Phoenix Arizona 85032
Oruka Therapeutics Investigative Site North Little Rock Arkansas 72117
Oruka Therapeutics Investigative Site Los Angeles California 90024
Oruka Therapeutics Investigative Site Los Angeles California 90045
Oruka Therapeutics Investigative Site San Diego California 92123
Oruka Therapeutics Investigative Site Miami Florida 33126
Oruka Therapeutics Investigative Site Rolling Meadows Illinois 60008
Oruka Therapeutics Investigative Site Plainfield Indiana 46168
Oruka Therapeutics Investigative Site Rockville Maryland 20850
Oruka Therapeutics Investigative Site Kew Gardens New York 11415
Oruka Therapeutics Investigative Site Chapel Hill North Carolina 27516
Oruka Therapeutics Investigative Site Cleveland Ohio 44106
Oruka Therapeutics Investigative Site Mason Ohio 45040
Oruka Therapeutics Investigative Site Portland Oregon 97201
Oruka Therapeutics Investigative Site Portland Oregon 97210
Oruka Therapeutics Investigative Site Philadelphia Pennsylvania 19104
Oruka Therapeutics Investigative Site Frisco Texas 75033
Oruka Therapeutics Investigative Site Houston Texas 77004
Oruka Therapeutics Investigative Site Webster Texas 77598
Oruka Therapeutics Investigative Site Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07290569, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 16, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07290569 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →